公开(公告)号：EP1773774A2

公开(公告)日：2007-04-18

申请号：EP05774700.8

申请日：2005-07-26

申请人： Merck & Co., Inc.

发明人： PINKERTON, Anthony, B. ,  VERNIER, Jean-Michel ,  CUBE, Rowena, V. ,  HUTCHINSON, John, H. ,  HUANG, Dehua ,  BONNEFOUS, Celine ,  GOVAK, Steven, P. ,  KAMENECKA, Theodore

IPC分类号： C07D213/02 ,  C07D215/00 ,  C07D217/00 ,  A61K31/44 ,  A61K31/47

CPC分类号： C07D311/16 ,  C07C45/71 ,  C07C49/84 ,  C07C69/734 ,  C07C69/92 ,  C07C217/76 ,  C07C217/92 ,  C07C235/42 ,  C07C255/54 ,  C07C323/12 ,  C07D205/04 ,  C07D209/08 ,  C07D213/30 ,  C07D213/53 ,  C07D213/64 ,  C07D213/65 ,  C07D213/68 ,  C07D213/70 ,  C07D213/71 ,  C07D213/74 ,  C07D213/84 ,  C07D213/89 ,  C07D215/20 ,  C07D217/02 ,  C07D231/56 ,  C07D233/20 ,  C07D233/60 ,  C07D235/06 ,  C07D235/08 ,  C07D235/10 ,  C07D235/16 ,  C07D235/18 ,  C07D239/34 ,  C07D257/04 ,  C07D263/58 ,  C07D271/10 ,  C07D277/74 ,  C07D307/80 ,  C07D311/22 ,  C07D311/24 ,  C07D311/58 ,  C07D401/04 ,  C07D417/04 ,  C07D471/04 ,  C07D473/38

摘要： The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

公开(公告)号：EP1853260A1

公开(公告)日：2007-11-14

申请号：EP06734961.3

申请日：2006-02-14

申请人： Merck & Co., Inc.

发明人： PINKERTON, Anthony, B. ,  CUBE, Rowena ,  HUTCHINSON, John ,  HUANG, Dehua ,  VERNIER, Jean-Michel ,  SHEN, Dong-Ming

IPC分类号： A61K31/44 ,  C07D401/00

CPC分类号： C07D231/38 ,  C07D231/12 ,  C07D231/22 ,  C07D401/12 ,  C07D403/12

摘要： Substituted pyrazole compounds such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

公开(公告)号：EP1773792A1

公开(公告)日：2007-04-18

申请号：EP05778397.9

申请日：2005-07-26

申请人： Merck & Co., Inc.

发明人： PINKERTON, Anthony, B. ,  VERNIER, Jean-Michel ,  CUBE, Rowena, V. ,  HUTCHINSON, John, H. ,  BONNEFOUS, Celine ,  KAMENECKA, Theodore

IPC分类号： C07D257/04

CPC分类号： C07C233/91 ,  C07C59/90 ,  C07C65/40 ,  C07C311/51 ,  C07C2601/08 ,  C07C2602/08 ,  C07D257/04 ,  C07D307/79 ,  C07D401/04

摘要： The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

摘要翻译： 本发明涉及作为代谢型谷氨酸受体的增强剂（包括mGluR2受体）的化合物，它们可用于治疗或预防与谷氨酸能力障碍相关的神经和精神疾病以及参与代谢型谷氨酸受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。

公开(公告)号：EP1807073A2

公开(公告)日：2007-07-18

申请号：EP05813869.4

申请日：2005-10-21

申请人： Merck & Co., Inc.

发明人： PINKERTON, Anthony, B. ,  VERNIER, Jean-Michel ,  CUBE, Rowena, V. ,  HUTCHINSON, John, H.

IPC分类号： A61K31/4164 ,  A61K31/4192 ,  A61K31/44 ,  C07D213/70

CPC分类号： C07D213/30 ,  C07D207/32 ,  C07D213/65 ,  C07D213/70 ,  C07D231/12 ,  C07D235/18 ,  C07D249/08

摘要： The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

公开(公告)号：EP1556038A2

公开(公告)日：2005-07-27

申请号：EP03793309.0

申请日：2003-08-22

申请人： Merck & Co., Inc.

发明人： CUBE, Rowena, V. ,  PINKERTON, Anthony, B. ,  VERNIER, Jean-Michel ,  ZHAO, Xiumin

IPC分类号： A61K31/41 ,  A61P25/00 ,  C07D257/04

CPC分类号： C07D257/04

摘要： The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.